Search research articles
Contact Us
Filters
Showing results (311-320 of 418) with videos related to
Page
of 42
Sort By:
Molecular Cancer Therapeutics
|
October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Ryan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Annals of Surgical Oncology
|
July 11, 2013
Age as a prognostic factor in patients with localized melanoma and regional metastases
Charles M Balch, Seng-jaw Soong, Jeffrey E Gershenwald, et al.
Cell Reports
|
December 7, 2017
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence
Katherine R Singleton, Lorin Crawford, Elizabeth Tsui, et al.
Cell
|
July 19, 2018
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, et al.
Cancer
|
December 10, 2021
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)
Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Cancer Immunology Research
|
May 20, 2014
Bevacizumab plus ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Donald Lawrence, Cecilia Lezcano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Page
of 42
Search research articles
Search
Showing results (311-320 of 418) with videos related to
Sort By:
Page
of 42
Molecular Cancer Therapeutics
|
October 25, 2019
A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer
Ryan J Sullivan, Antoine Hollebecque, Keith T Flaherty, et al.
Annals of Surgical Oncology
|
July 11, 2013
Age as a prognostic factor in patients with localized melanoma and regional metastases
Charles M Balch, Seng-jaw Soong, Jeffrey E Gershenwald, et al.
Cell Reports
|
December 7, 2017
Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence
Katherine R Singleton, Lorin Crawford, Elizabeth Tsui, et al.
Cell
|
July 19, 2018
Toward Minimal Residual Disease-Directed Therapy in Melanoma
Florian Rambow, Aljosja Rogiers, Oskar Marin-Bejar, et al.
Cancer
|
December 10, 2021
A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152)
Angela R Bradbury, Ju-Whei Lee, Jill Bennett Gaieski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 14, 2022
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600-Mutant Unresectable or Metastatic Melanoma
Reinhard Dummer, Georgina V Long, Caroline Robert, et al.
Cancer Immunology Research
|
May 20, 2014
Bevacizumab plus ipilimumab in patients with metastatic melanoma
F Stephen Hodi, Donald Lawrence, Cecilia Lezcano, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials
Dirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 20, 2023
National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
Funda Meric-Bernstam, James M Ford, Peter J O'Dwyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Page
of 42